1. At the 2012 annual meeting of shareholders of Hi-Tech Pharmacal Co., Inc. (the "Company") held on November 7, 2012 ("2012 Annual Meeting"), the shareholders elected the following individuals as directors of the Company until the Company's 2013 annual meeting of shareholders as follows:

                         For     Withheld Broker Non-Votes

David Seltzer         9,812,448   245,174    1,933,965
Reuben Seltzer        9,577,338   480,284    1,933,965
Martin M. Goldwyn     8,283,830 1,773,792    1,933,965
Yashar Hirshaut, M.D. 9,179,948   877,674    1,933,965
Jack van Hulst        9,180,100   877,522    1,933,965
Anthony J. Puglisi    9,960,420    97,202    1,933,965
Bruce W. Simpson      7,882,789 2,174,833    1,933,965

2. At the 2012 Annual Meeting, the Company's shareholders approved and adopted the Company's 2012 Incentive Compensation Plan as follows:

For Against Abstain Broker Non-Votes 6,486,777 3,565,361 5,484 1,933,965

3. At the 2012 Annual Meeting, the Company's shareholders ratified the appointment of EisnerAmper LLP as the Company's independent auditors for the fiscal year ending April 30, 2013 as follows:

11,921,886 65,904 3,797

4. At the 2012 Annual Meeting, the Company's shareholders approved, on a non-binding advisory basis, the compensation paid to the Company's named executive officers, as described in the Company's proxy statement as follows:

For Against Abstain Broker Non-Votes 9,707,558 326,072 23,992 1,933,965